Global Fairness in Drug Pricing Act

HR 3493, the Global Fairness in Drug Pricing Act, requires the U.S. Health and Human Services Secretary to establish price targets for pharmaceutical manufacturers, ensuring U.S. drug prices align with those in comparable developed countries. It directs the HHS Secretary to certify safe importation of drugs from low-cost countries and facilitate direct-to-consumer purchasing programs at the set prices. The bill also authorizes antitrust enforcement against drug companies for anticompetitive practices and mandates a study on whether manufacturers engage in unfair pricing that forces U.S. patients to subsidize global drug research. This legislation directly affects pharmaceutical manufacturers and American patients seeking affordable prescription drugs.